FRS2Β, a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding

Oncogene

Volumn 29, Issue 21, 2010, Pages 3087-3099

  Iejima, D ^a   Minegishi, Y ^a   Takenaka, K ^b,c   Siswanto, A ^a,d   Watanabe, M ^a   Huang, L ^e   Watanabe, T ^d   Tanaka, F ^b,f   Kuroda, M ^g   Gotoh, N ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Koseikai Takeda Hospital   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e RIKEN   (Japan)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

FRS2; FRS3; HER; NSCLC; Prognosis; SNT2

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2 BETA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR; FRS3 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MYRISTIC ACID; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AGED; AMINO ACID SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL MEMBRANE; CONTROLLED STUDY; FEEDBACK SYSTEM; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR DOCKING; MOLECULAR MECHANICS; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; CELL DIVISION; CLONOGENIC ASSAY; CULTURE TECHNIQUE; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; KINETICS; LUNG TUMOR; METABOLISM; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL MEMBRANE; COLONY-FORMING UNITS ASSAY; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYRISTIC ACID; PROGNOSIS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER;

EID: 77952955054     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.69     Document Type: Article

References (30)

1. Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T. (1991). The transforming potential of the c-erbB2 protein is regulated by its authophosphorylation at the carbodyl-terminal domain. Mol Cell Biol 11: 833-842.
2. Bargmann CI, Weinberg RA. (1988). Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7: 2043-2052.
3. Baselga J, Arteaga CL. (2005). Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459.
4. Blume-Jensen P, Hunter T. (2001). Oncogenic kinase signalling. Nature 411: 355-365.
5. Butch ER, Guan KL. (1996). Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2. J Biol Chem 271: 4230-4235.
6. Eswarakumar VP, Lax I, Schlessinger J. (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149.
7. Gotoh N. (2008). Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 99: 1319-1325.
8. Gotoh N. (2009). Feedback inhibitors of the epidermal growth factor receptor signaling pathways. Int J Biochem Cell Biol 41: 511-515.
9. Gotoh N, Ito M, Yamamoto S, Yoshino I, Song N, Wang Y et al. (2004a). Tyrosine phosphorylation sites on FRS2alpha responsible for Shp2 recruitment are critical for induction of lens and retina. Proc Natl Acad Sci USA 101: 17144-17149.
10. Gotoh N, Laks S, Nakashima M, Lax I, Schlessinger J. (2004b). FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts. FEBS Lett 564: 14-18.
11. Gotoh N, Manova K, Tanaka S, Murohashi M, Hadari Y, Lee A et al. (2005). The docking protein FRS2alpha is an essential component of multiple fibroblast growth factor responses during early mouse development. Mol Cell Biol 25: 4105-4116.
12. Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J. (2001). Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci USA 98: 8578-8583.
13. Huang L, Gotoh N, Zhang S, Shibuya M, Yamamoto T, Tsuchida N. (2004). SNT-2 interacts with ERK2 and negatively regulates ERK2 signaling in response to EGF stimulation. Biochem Biophys Res Commun 324: 1011-1017.
14. Huang L, Watanabe M, Chikamori M, Kido Y, Yamamoto T, Shibuya M et al. (2006). Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways. Oncogene 25: 6457-6466.
15. Hynes NE, Lane HA. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
17. Kawamura-Tsuzuku J, Suzuki T, Yoshida Y, Yamamoto T. (2004). Nuclear localization of Tob is important for regulation of its antiproliferative activity. Oncogene 23: 6630-6638.
18. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T et al. (2003). Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 31: 1007-1014.
19. Lax I, Wong A, Lamothe B, Lee A, Frost A, Hawes J et al. (2002). The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. Mol Cell 10: 709-719.
20. Lee T, Hoofnagle AN, Kabuyama Y, Stroud J, Min X, Goldsmith EJ et al. (2004). Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. Mol Cell 14: 43-55.
21. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
22. Sato T, Gotoh N. (2009). The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. Expert Opin Ther Targets 13: 689-700.
23. Schlessinger J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
24. Sharrocks AD, Yang SH, Galanis A. (2000). Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem Sci 25: 448-453.
25. Sonobe M, Manabe T, Wada H, Tanaka F. (2005). Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 93: 355-363.
26. Sonobe M, Manabe T, Wada H, Tanaka F. (2006). Lung adenocarci-noma harboring mutations in the ERBB2 kinase domain. J Mol Diagn 8: 351-356.
27. Tanoue T, Adachi M, Moriguchi T, Nishida E. (2000). A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2: 110-116.
28. Tanoue T, Nishida E. (2003). Molecular recognitions in the MAP kinase cascades. Cell Signal 15: 455-462.
29. Yamamoto S, Yoshino I, Shimazaki T, Murohashi M, Hevner RF, Lax I et al. (2005). Essential role of Shp2-binding sites on FRS2alpha for corticogenesis and for FGF2-dependent proliferation of neural progenitor cells. Proc Natl Acad Sci USA 102: 15983-15988.
30. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.